tiprankstipranks
Trending News
More News >
MiMedx Group (MDXG)
NASDAQ:MDXG
US Market
Advertisement

MiMedx Group (MDXG) AI Stock Analysis

Compare
477 Followers

Top Page

MDXG

MiMedx Group

(NASDAQ:MDXG)

Rating:78Outperform
Price Target:
$8.00
▲(11.27%Upside)
MiMedx Group's overall stock score reflects its strong financial performance and positive earnings call insights. While technical analysis and corporate events support a favorable outlook, the high valuation and potential regulatory challenges warrant cautious optimism.
Positive Factors
Product Sales
MDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.
Strategic Initiatives
Management remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.
Negative Factors
Reimbursement Uncertainty
Continuing reimbursement uncertainty disrupted the business in the physician office setting.

MiMedx Group (MDXG) vs. SPDR S&P 500 ETF (SPY)

MiMedx Group Business Overview & Revenue Model

Company DescriptionMiMedx Group, Inc. is a regenerative medicine company, primarily focusing on the development and commercialization of advanced wound care and therapeutic biologics. The company is known for its innovative use of human placental tissue to create a range of products designed to support healing and tissue repair. These products are used in various medical sectors, including wound care, orthopedics, and sports medicine, and are distributed primarily in the United States.
How the Company Makes MoneyMiMedx Group generates revenue primarily through the sale of its placental-based tissue products. These products are marketed to hospitals, clinics, and healthcare professionals who use them in treating chronic and acute wounds, as well as in surgical and sports medicine applications. The company has established partnerships with healthcare providers and distributors to expand its market reach and enhance product accessibility. Key revenue streams include direct sales to medical facilities and distribution agreements with third-party partners. Additionally, MiMedx invests in research and development to innovate and expand its product offerings, which can lead to new revenue opportunities in emerging therapeutic areas.

MiMedx Group Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: 10.28%|
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Positive
The earnings call reflects strong financial performance with record revenue and EBITDA figures, robust growth in key segments, and strategic advancements. However, concerns surrounding regulatory changes and trial enrollment challenges present potential headwinds. Despite these challenges, the overall sentiment remains positive due to the company's strong financial position and increased guidance.
Q2-2025 Updates
Positive Updates
Record Quarterly Revenue and EBITDA
The company achieved the highest quarterly revenue and adjusted EBITDA in its history, with a 13% increase in net sales to $99 million and an adjusted EBITDA of $24 million, representing 25% of net sales.
Strong Performance in Wound and Surgical Franchises
Both the Wound and Surgical franchises experienced double-digit growth, with the Surgical business growing by 15% and Wound sales increasing by 12% compared to the prior year.
Cash Flow and Balance Sheet Improvements
The company generated solid cash flow, ending the quarter with a cash balance of $119 million, an increase of $12 million, and expects to end the year with over $150 million in cash.
Increased Full Year Revenue Guidance
Due to strong performance and current momentum, the company increased its full-year revenue growth outlook from high single digits to low double digits.
Strategic Initiatives and Market Expansion
The company made progress with new product launches like EPIEXRESS and collaborations with Vaporox Inc., and plans to expand its offerings in the wound care and surgical markets.
Negative Updates
Challenges with EPIEFFECT Enrollment
Enrollment for the EPIEFFECT randomized controlled trial is progressing slower than expected due to capacity issues, delaying interim results.
Regulatory and Reimbursement Changes
Upcoming changes to the Medicare reimbursement system and potential reduction in market size due to fixed pricing could impact future revenue.
Company Guidance
During the MiMedx Second Quarter 2025 Operating and Financial Results Conference Call, the company reported a 13% year-over-year increase in net sales, reaching a record $99 million. The adjusted gross profit margin stood at 84%, while adjusted EBITDA was $24 million, accounting for 25% of net sales. The company ended the quarter with a cash balance of $119 million, an increase of $12 million from the previous quarter, and expects to end the year with more than $150 million in cash. MiMedx revised its full-year revenue growth outlook from high single digits to low double digits and anticipates a full-year adjusted EBITDA margin above 20%. The company is also preparing for Medicare reimbursement reforms set for January 1, 2026, while continuing to innovate and diversify its product portfolio, particularly in the wound care and surgical markets.

MiMedx Group Financial Statement Overview

Summary
MiMedx Group has shown strong revenue growth and profitability improvements, with a robust gross profit margin of 81.9% and a positive net profit margin of 11.4% for TTM 2025. The solid balance sheet with low leverage and strong cash flow generation underscores financial stability.
Income Statement
82
Very Positive
MiMedx Group has shown strong growth in revenue over the observed periods, with a notable increase from $267.8M in 2022 to $352.4M in TTM (Trailing-Twelve-Months) 2025. Gross profit margin is robust at 81.9% for TTM, indicating efficient cost management. The net profit margin has turned positive, reaching 11.4% in TTM 2025 from negative figures in previous years, signaling improved profitability. However, the decline in EBIT from 2024 to TTM 2025 suggests some operational cost challenges.
Balance Sheet
76
Positive
The company's balance sheet reflects a solid equity position with an equity ratio of 74.98% in TTM 2025, indicating a strong capital structure. The debt-to-equity ratio is very low at 0.01, showcasing minimal leverage, which reduces financial risk. Return on equity is positive at 19.81%, reflecting efficient use of equity to generate profits. Nonetheless, the high level of cash reserves relative to debt suggests missed opportunities for investment or growth.
Cash Flow
88
Very Positive
MiMedx Group demonstrates strong cash flow generation with free cash flow growing significantly, highlighted by a free cash flow of $68.7M in TTM 2025. The operating cash flow to net income ratio is favorable, indicating efficient cash generation from operations. Furthermore, the free cash flow to net income ratio of 1.71 signifies robust cash conversion efficiency. Overall, the cash flow position is solid, underpinning financial stability and flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue352.38M348.88M321.48M267.84M258.62M248.23M
Gross Profit288.54M288.81M266.84M219.53M215.33M208.90M
EBITDA54.95M64.34M40.52M-10.69M-1.89M-45.76M
Net Income40.18M42.42M67.44M-30.20M-10.29M-49.28M
Balance Sheet
Total Assets270.42M263.92M239.05M171.43M187.93M202.03M
Cash, Cash Equivalents and Short-Term Investments106.43M104.42M82.00M65.95M87.08M95.81M
Total Debt18.66M24.84M48.10M48.59M48.13M47.70M
Total Liabilities67.64M70.81M96.33M189.42M187.85M202.18M
Stockholders Equity202.78M193.11M142.72M-17.99M82.00K-150.00K
Cash Flow
Free Cash Flow68.32M64.52M24.79M-20.58M-5.45M-34.82M
Operating Cash Flow67.55M66.20M26.77M-17.89M-1.98M-30.26M
Investing Cash Flow-3.96M-9.58M-2.15M-2.66M-3.40M-4.55M
Financing Cash Flow-3.61M-34.20M-8.57M-580.00K-3.35M61.56M

MiMedx Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.19
Price Trends
50DMA
6.47
Positive
100DMA
6.85
Positive
200DMA
7.57
Negative
Market Momentum
MACD
0.12
Negative
RSI
61.85
Neutral
STOCH
40.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Positive. The current price of 7.19 is above the 20-day moving average (MA) of 6.72, above the 50-day MA of 6.47, and below the 200-day MA of 7.57, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 40.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDXG.

MiMedx Group Risk Analysis

MiMedx Group disclosed 40 risk factors in its most recent earnings report. MiMedx Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

MiMedx Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$985.17M24.1816.62%6.85%-67.67%
63
Neutral
$1.01B-36.26%127.33%21.31%
55
Neutral
$1.60B-188.03%-11.42%0.26%
53
Neutral
$1.87B-57.19%-0.33%-3.59%
52
Neutral
$975.09M-51.85%11070.12%32.07%
51
Neutral
$7.30B0.27-62.71%2.44%15.02%0.60%
49
Neutral
$1.46B-23.20%24.49%5.14%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MDXG
MiMedx Group
7.19
0.51
7.63%
CLDX
Celldex
21.98
-15.57
-41.46%
IOVA
Iovance Biotherapeutics
2.57
-5.59
-68.50%
ARDX
Ardelyx
4.24
-1.26
-22.91%
OCUL
Ocular Therapeutix
11.58
3.51
43.49%
LQDA
Liquidia Technologies
18.69
7.10
61.26%

MiMedx Group Corporate Events

Business Operations and StrategyFinancial Disclosures
MiMedx Group Reports Record Q2 2025 Financial Results
Positive
Jul 30, 2025

MiMedx Group announced record financial results for the second quarter of 2025, with net sales reaching $99 million, a 13% increase from the previous year. The company achieved its highest quarterly net sales, driven by growth in its Wound and Surgical franchises, and reported a net income of $10 million. MiMedx also raised its net sales growth expectations for 2025, anticipating low double-digit growth. The company is engaging with CMS on proposed reimbursement reforms for skin substitutes, which could impact future operations and market positioning.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

Shareholder Meetings
MiMedx Group Holds Annual Shareholder Meeting
Neutral
Jun 20, 2025

On June 18, 2025, MiMedx Group held its Annual Meeting of Shareholders, where 85.7% of the voting shares were represented. During the meeting, nine directors were re-elected, an advisory resolution on executive compensation was approved, Deloitte & Touche LLP was ratified as the independent auditor for 2025, an amendment to the 2016 Equity and Cash Incentive Plan was approved, and it was decided that the advisory vote on executive compensation would occur annually.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
MiMedx Group Highlights Growth at Healthcare Conference
Positive
May 13, 2025

MiMedx Group announced its participation in the Bank of America Securities 2025 Healthcare Conference, highlighting its updated investor presentation. The company is poised for growth with expectations of expanding its product portfolio and increasing its presence in surgical settings, driven by favorable market trends and innovative placental-derived products. The announcement underscores MiMedx’s strategic focus on expanding its global footprint and enhancing its product offerings to drive profitability and stakeholder value.

The most recent analyst rating on (MDXG) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025